Next Article in Journal
Enhanced Antioxidant Capacity and Anti-Ageing Biomarkers after Diet Micronutrient Supplementation
Previous Article in Journal
Challenges and Opportunities of MicroRNAs in Lymphomas
Article Menu

Export Article

Open AccessArticle
Molecules 2014, 19(9), 14782-14793; https://doi.org/10.3390/molecules190914782

Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model

Department of Geriatrics, the 2nd Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
*
Author to whom correspondence should be addressed.
Received: 17 July 2014 / Revised: 18 August 2014 / Accepted: 1 September 2014 / Published: 17 September 2014
(This article belongs to the Section Medicinal Chemistry)
View Full-Text   |   Download PDF [743 KB, uploaded 17 September 2014]   |  

Abstract

Diabetes mellitus (DM) has been recognized as a major health problem. Emodin (Emo) has been reported to exhibit protective effects against diabetic nephropathy. However, little has been known about the effect of Emo on diabetic cardiomyopathy (DCM). A type 2 DM model was induced in rats by low dose streptozotocin (STZ) combined with high energy intake. We found that Emo-treated groups displayed significantly higher body weight (BW) and lower heart weight (HW)/BW. Furthermore, Emo could significantly decrease blood glucose, total cholesterol (TG) levels, and triglyceride (TC) levels in diabetic rats. Moreover, the Emo-treated group showed a marked increase in heart rate (HR) and showed lower left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular posterior wall thickness (LWPWT), and interventricular septal diastolic wall thickness (IVSD). Emo induced a significant increase in phosphorylation of Akt and GSK-3β in myocardium. These results suggest that Emo may have great therapeutic potential in the treatment of DCM by Akt/GSK-3β signaling pathway. View Full-Text
Keywords: emodin; diabetic cardiomyopathy; blood glucose; Akt; GSK-3β emodin; diabetic cardiomyopathy; blood glucose; Akt; GSK-3β
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Wu, Z.; Chen, Q.; Ke, D.; Li, G.; Deng, W. Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model. Molecules 2014, 19, 14782-14793.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top